Private Wealth Asset Management LLC raised its position in Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 195.8% during the third quarter, according to its most recent filing with the SEC. The firm owned 51,671 shares of the biopharmaceutical company’s stock after purchasing an additional 34,201 shares during the period. Private Wealth Asset Management LLC’s holdings in Bristol Myers Squibb were worth $3,211,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently modified their holdings of BMY. Primecap Management Co. CA acquired a new stake in shares of Bristol Myers Squibb during the second quarter worth $1,436,115,000. Legal & General Group Plc acquired a new position in Bristol Myers Squibb in the second quarter valued at $980,862,000. BlackRock Inc. lifted its holdings in Bristol Myers Squibb by 5.1% in the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock valued at $10,393,783,000 after buying an additional 8,702,106 shares during the period. State Street Corp boosted its position in Bristol Myers Squibb by 7.3% during the second quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company’s stock valued at $6,093,755,000 after acquiring an additional 7,192,724 shares during the last quarter. Finally, Caisse de depot et placement du Quebec bought a new stake in Bristol Myers Squibb during the second quarter valued at $243,646,000. 76.41% of the stock is owned by institutional investors.
Insider Transactions at Bristol Myers Squibb
In other news, Director Julia Haller sold 3,800 shares of the business’s stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $63.31, for a total value of $240,578.00. Following the completion of the sale, the director owned 30,279 shares of the company’s stock, valued at approximately $1,916,963.49. The trade was a 11.15% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Phil M. Holzer sold 500 shares of the firm’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the transaction, the senior vice president owned 16,862 shares in the company, valued at $1,138,185. This represents a 2.88% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 0.05% of the company’s stock.
Analyst Ratings Changes
A number of analysts have weighed in on the company. BMO Capital Markets reiterated a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, July 27th. Piper Sandler dropped their price objective on Bristol Myers Squibb from $82.00 to $78.00 and set an “overweight” rating on the stock in a research note on Monday, October 26th. Daiwa Securities Group upped their target price on Bristol Myers Squibb from $53.00 to $66.00 and gave the company a “neutral” rating in a research report on Tuesday, August 4th. Roth Capital started coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They set a “buy” rating and a $75.00 price target on the stock. Finally, Morgan Stanley lowered their price target on Bristol Myers Squibb from $41.00 to $40.00 and set an “underweight” rating for the company in a research report on Friday, October 30th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, sixteen have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $65.46.
Check Out Our Latest Analysis on BMY
Trending Headlines about Bristol Myers Squibb
Here are a few of the latest headlines about BMY:
- Positive Sentiment: A second investigational drug candidate from BMS’s protein-degradation partnership with Evotec received FDA IND acceptance, advancing another potential medicine toward clinical testing. The partnership’s first candidate entered Phase 1 in March 2026. Evotec and Bristol Myers Squibb Advance Strategic Protein Degradation Partnership with Second IND Acceptance
- Positive Sentiment: BMS reported preliminary Phase 3 data indicating that KarXT reduced hallucinations and delusions associated with Alzheimer’s disease. Further evidence could support the drug’s potential, though the reports do not provide detailed efficacy results. Bristol’s schizophrenia drug helps Alzheimer’s-related psychosis symptoms, preliminary data shows
- Negative Sentiment: A technical report said BMY shares fell below their 200-day moving average, a potentially bearish signal for momentum-oriented investors. Separately, Zacks favored Merck over BMS, citing stronger performance and growth drivers. Bristol Myers Squibb Stock Price Breaks Below 200 Day Moving Average – What’s Next?
Bristol Myers Squibb Price Performance
Bristol Myers Squibb stock opened at $58.33 on Friday. The business has a fifty day moving average price of $61.55 and a 200-day moving average price of $60.42. The firm has a market capitalization of $119.23 billion, a P/E ratio of 12.93, a PEG ratio of 0.31 and a beta of 0.20. Bristol Myers Squibb Company has a one year low of $45.26 and a one year high of $68.64. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.59 and a quick ratio of 1.44.
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last posted its earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share for the quarter, topping analysts’ consensus estimates of $1.10 by $0.25. Bristol Myers Squibb had a net margin of 18.47% and a return on equity of 60.48%. The business had revenue of $13.07 billion for the quarter, compared to analyst estimates of $12.72 billion. During the same quarter in the prior year, the firm posted $1.63 EPS. Bristol Myers Squibb’s revenue was up 6.9% on a year-over-year basis. As a group, equities research analysts forecast that Bristol Myers Squibb Company will post 6.46 EPS for the current year.
Bristol Myers Squibb Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd were given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 4.3%. The ex-dividend date was Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 55.88%.
Bristol Myers Squibb Profile
Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.
Featured Stories
- Five stocks we like better than Bristol Myers Squibb
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY – Free Report).
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
